{"disease":{"id":"esophageal-squamous-cell-carcinomas","name":"esophageal squamous cell carcinomas"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04892849","title":"Clinical Benefit and Biomarker Analysis of Combination of PD-1/PD-L1 Immune Checkpoint Inhibitors and Radiotherapy","phase":"","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"University of Erlangen-Nürnberg Medical School","has_results":false},{"nct_id":"NCT05103501","title":"Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":54,"lead_sponsor_name":"Shanghai Chest Hospital","has_results":false},{"nct_id":"NCT05233436","title":"PF-07265028 As Single Agent And In Combination With Sasanlimab in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":21,"lead_sponsor_name":"Pfizer","has_results":false}],"total":3},"guidelines":[],"source":"Drug Landscape verified database"}